39010704|t|Sodium-glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study.
39010704|a|INTRODUCTION: This study aims to evaluate the effects of sodium-glucose cotransporter 1 inhibitors (SGLT1i) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) on neurodegenerative disorders and to investigate the role of hemoglobin A1c (HbA1c) levels. METHODS: Utilizing drug target Mendelian randomization, we employed single nucleotide polymorphisms (SNPs) proximal to the SLC5A1 and SLC5A2 genes to analyze the influence of SGLT1i and SGLT2i on Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), frontotemporal dementia (FTD), Lewy body dementia (LBD), and amyotrophic lateral sclerosis (ALS), with type 2 diabetes (T2D) as a positive control. An additional analysis examined the impact of HbA1c levels on the same disorders. RESULTS: SGLT1i exhibited a significant association with decreased risk for ALS and MS. Conversely, SGLT2i were linked to an increased risk of AD, PD, and MS. Elevated HbA1c levels, independent of SGLT1 and SGLT2 effects, were associated with an increased risk of PD. Sensitivity analyses supported the robustness of these findings. CONCLUSION: Our study suggests that SGLT1i may confer protection against ALS and MS, whereas SGLT2i could elevate the risk of AD, PD, and MS. Additionally, elevated HbA1c levels emerged as a risk factor for PD. These findings underscore the importance of personalized approaches in the utilization of SGLT inhibitors, considering their varying impacts on the risks of neurodegenerative diseases.
39010704	56	83	neurodegenerative disorders	Disease	MESH:D019636
39010704	230	271	sodium-glucose cotransporter 2 inhibitors	Chemical	-
39010704	273	279	SGLT2i	Chemical	-
39010704	284	311	neurodegenerative disorders	Disease	MESH:D019636
39010704	497	503	SLC5A1	Gene	6523
39010704	508	514	SLC5A2	Gene	6524
39010704	560	566	SGLT2i	Chemical	-
39010704	570	589	Alzheimer's disease	Disease	MESH:D000544
39010704	591	593	AD	Disease	MESH:D000544
39010704	596	615	Parkinson's disease	Disease	MESH:D010300
39010704	617	619	PD	Disease	MESH:D010300
39010704	622	640	multiple sclerosis	Disease	MESH:D009103
39010704	642	644	MS	Disease	MESH:D009103
39010704	647	670	frontotemporal dementia	Disease	MESH:D057180
39010704	672	675	FTD	Disease	MESH:D057180
39010704	678	696	Lewy body dementia	Disease	MESH:D020961
39010704	698	701	LBD	Disease	MESH:D020961
39010704	708	737	amyotrophic lateral sclerosis	Disease	MESH:D000690
39010704	739	742	ALS	Disease	MESH:D000690
39010704	750	765	type 2 diabetes	Disease	MESH:D003924
39010704	767	770	T2D	Disease	MESH:D003924
39010704	953	956	ALS	Disease	MESH:D000690
39010704	961	963	MS	Disease	MESH:D009103
39010704	977	983	SGLT2i	Chemical	-
39010704	1020	1022	AD	Disease	MESH:D000544
39010704	1024	1026	PD	Disease	MESH:D010300
39010704	1032	1034	MS	Disease	MESH:D009103
39010704	1074	1079	SGLT1	Gene	6523
39010704	1084	1089	SGLT2	Gene	6524
39010704	1141	1143	PD	Disease	MESH:D010300
39010704	1283	1286	ALS	Disease	MESH:D000690
39010704	1291	1293	MS	Disease	MESH:D009103
39010704	1303	1309	SGLT2i	Chemical	-
39010704	1336	1338	AD	Disease	MESH:D000544
39010704	1340	1342	PD	Disease	MESH:D010300
39010704	1348	1350	MS	Disease	MESH:D009103
39010704	1417	1419	PD	Disease	MESH:D010300
39010704	1511	1526	SGLT inhibitors	Chemical	-
39010704	1578	1604	neurodegenerative diseases	Disease	MESH:D019636

